{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:52:47Z","timestamp":1792432367507,"version":"4.5.0"},"reference-count":73,"publisher":"Frontiers Media SA","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2014.00064","type":"journal-article","created":{"date-parts":[[2014,4,14]],"date-time":"2014-04-14T05:00:26Z","timestamp":1397451626000},"source":"Crossref","is-referenced-by-count":1304,"title":["Targeting PI3K\/Akt\/mTOR Signaling in Cancer"],"prefix":"10.3389","volume":"4","author":[{"given":"Camillo","family":"Porta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Paglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Mosca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2014,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1101\/gad.13.22.2905","article-title":"Cellular survival: a play in three Akts","volume":"13","author":"Datta","year":"1999","journal-title":"Genes Dev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/nature04869","article-title":"Ras, PI3K, and mTOR signalling controls tumor cell growth","volume":"441","author":"Shaw","year":"2006","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/nrd1902","article-title":"Exploiting the PI3K\/Akt pathway for cancer drug discovery","volume":"4","author":"Hennessy","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"B4","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2174\/156801105774574649","article-title":"Inhibition of PI3K\/Akt signaling: an emerging paradigm for targeted cancer therapy","volume":"5","author":"Chen","year":"2005","journal-title":"Curr Med Chem Anticancer Agents"},{"key":"B5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1146\/annurev.biochem.67.1.481","article-title":"Phosphoinositide kinases","volume":"67","author":"Fruman","year":"1998","journal-title":"Annu Rev Biochem"},{"key":"B6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","article-title":"PI3K\/Akt signalling pathway and cancer","volume":"30","author":"Fresno-Vara","year":"2004","journal-title":"Cancer Treat Rev"},{"key":"B7","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1101\/gad.14.9.1027","article-title":"Protein-protein interactions define specificity in signal transduction","volume":"14","author":"Pawson","year":"2000","journal-title":"Genes Dev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"10983","DOI":"10.1073\/pnas.211430998","article-title":"Akt plays a central role in tumorigenesis","volume":"98","author":"Testa","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B9","doi-asserted-by":"publisher","first-page":"6073","DOI":"10.1038\/sj.onc.1204736","article-title":"Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer","volume":"20","author":"Chen","year":"2001","journal-title":"Oncogene"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e39945","DOI":"10.1371\/journal.pone.0039945","article-title":"Cross-talk between NFkB and the PI3-kinase\/Akt pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis","volume":"7","author":"Hussain","year":"2012","journal-title":"PLoS One"},{"key":"B11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4161\/cc.2.4.433","article-title":"Multiple roles of the PI3K\/PKB (Akt) pathway in cell cycle progression","volume":"2","author":"Liang","year":"2003","journal-title":"Cell Cycle"},{"key":"B12","doi-asserted-by":"publisher","first-page":"7493","DOI":"10.1038\/sj.onc.1209087","article-title":"Akt crystal structure and Akt-specific inhibitors","volume":"24","author":"Kumar","year":"2005","journal-title":"Oncogene"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR","volume":"18","author":"Hay","year":"2004","journal-title":"Genes Dev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2004.06.007","article-title":"The LKB1 tumor suppressor negatively regulates mTOR signaling","volume":"6","author":"Shaw","year":"2004","journal-title":"Cancer Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.cellsig.2009.01.004","article-title":"Akt-dependent and -independent mechanisms of mTOR regulation in cancer","volume":"21","author":"Memmott","year":"2009","journal-title":"Cell Signal"},{"key":"B16","first-page":"3581","article-title":"Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells","volume":"59","author":"Grewe","year":"1999","journal-title":"Cancer Res"},{"key":"B17","first-page":"299","article-title":"mTOR as a positive regulator of tumor cell responses to hypoxia","volume":"279","author":"Abraham","year":"2004","journal-title":"Curr Top Microbiol Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"7034","DOI":"10.1038\/sj.onc.1203183","article-title":"The PTEN\/MMAC1\/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells","volume":"18","author":"Lu","year":"1999","journal-title":"Oncogene"},{"key":"B19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1006\/excr.2000.5130","article-title":"PTEN: life as a tumor suppressor","volume":"264","author":"Simpson","year":"2001","journal-title":"Exp Cell Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"727","DOI":"10.7164\/antibiotics.28.727","article-title":"Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization","volume":"28","author":"Seghal","year":"1975","journal-title":"J Antibiot (Tokyo)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0305-7372(81)80006-0","article-title":"New antitumor substances of natural origin","volume":"8","author":"Douros","year":"1981","journal-title":"Cancer Treat Rev"},{"key":"B22","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nrd2062","article-title":"Current development of mTOR inhibitors as anticancer agents","volume":"5","author":"Faivre","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"B23","doi-asserted-by":"publisher","first-page":"5755","DOI":"10.1158\/1078-0432.CCR-06-0118","article-title":"A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer","volume":"12","author":"Hidalgo","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator\u00e2\u20ac\u2122s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1200\/JCO.2007.12.0345","article-title":"Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies","volume":"26","author":"Mita","year":"2008","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1093\/annonc\/mds602","article-title":"Phase I\/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma","volume":"24","author":"Mita","year":"2013","journal-title":"Ann Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1200\/JCO.2012.45.5766","article-title":"Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy","volume":"31","author":"Demetri","year":"2013","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors","volume":"26","author":"O\u00e2\u20ac\u2122Donnell","year":"2008","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ejca.2011.11.027","article-title":"Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study","volume":"48","author":"Calvo","year":"2012","journal-title":"Eur J Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/bjc.2012.89","article-title":"Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis","volume":"106","author":"Bracarda","year":"2012","journal-title":"Br J Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.eururo.2011.12.057","article-title":"Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 trial","volume":"61","author":"Porta","year":"2012","journal-title":"Eur Urol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000338371","article-title":"Angiogenesis in neuroendocrine tumors: therapeutic applications","volume":"97","author":"Scoazec","year":"2013","journal-title":"Neuroendocrinology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1046\/j.1365-2559.1998.00321.x","article-title":"Expression of vascular endothelial growth factor in digestive neuroendocrine tumours","volume":"32","author":"Terris","year":"1998","journal-title":"Histopathology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1159\/000289569","article-title":"VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K\/Akt\/mTOR pathway","volume":"91","author":"Villaume","year":"2010","journal-title":"Neuroendocrinology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1200\/JCO.2008.16.7858","article-title":"Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","article-title":"Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial","volume":"28","author":"Yao","year":"2010","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1210\/jc.2011-0666","article-title":"Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus","volume":"96","author":"Yao","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomized, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"issue":"Suppl 4","key":"B42","doi-asserted-by":"crossref","first-page":"A157","DOI":"10.1200\/jco.2012.30.4_suppl.157","article-title":"Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET)","volume":"30","author":"Yao","year":"2012","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.seminoncol.2012.11.003","article-title":"Systemic therapeutic options for carcinoid","volume":"40","author":"Pavel","year":"2013","journal-title":"Semin Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"B45","doi-asserted-by":"publisher","first-page":"S463","DOI":"10.1158\/0008-5472.CAN-12-3923","article-title":"Effect of everolimus treatment on markers angiogenesis in patients with advanced pancreatic neuroendocrine tumours (pNET) results from the phase III RADIANT-3 study","volume":"47","author":"Yao","year":"2011","journal-title":"Eur J Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1158\/0008-5472.CAN-12-3923","article-title":"Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience","volume":"73","author":"Yao","year":"2013","journal-title":"Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.critrevonc.2012.03.004","article-title":"Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going?","volume":"84","author":"Fedele","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"7475","DOI":"10.1038\/sj.onc.1209090","article-title":"Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease","volume":"24","author":"Astrinidis","year":"2005","journal-title":"Oncogene"},{"key":"B50","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"key":"B51","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.ejca.2011.02.014","article-title":"Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma","volume":"47","author":"Porta","year":"2011","journal-title":"Eur J Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"B54","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nri3198","article-title":"Regulation and function of mTOR signalling in T cell fate decisions","volume":"12","author":"Chi","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fonc.2013.00108","article-title":"Targeting PI3K in cancer: any good news?","volume":"3","author":"Martini","year":"2013","journal-title":"Front Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1016\/j.juro.2009.08.085","article-title":"Phosphatidylinositol-3-kinase\/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase\/ Akt inhibitors","volume":"182","author":"Porta","year":"2009","journal-title":"J Urol"},{"key":"B57","doi-asserted-by":"crossref","first-page":"371","DOI":"10.18632\/oncotarget.477","article-title":"Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment","volume":"3","author":"Martelli","year":"2012","journal-title":"Oncotarget"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1517\/13543784.2010.520701","article-title":"Akt inhibitors in clinical development for the treatment of cancer","volume":"19","author":"Pal","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"B59","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1200\/JCO.2001.19.21.4150","article-title":"Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer","volume":"19","author":"Leonard","year":"2001","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"376","DOI":"10.5732\/cjc.012.10287","article-title":"Molecular mechanisms of tumor resistance to PI3K-mTOR targeted therapy","volume":"32","author":"Tan","year":"2013","journal-title":"Chin J Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol Cell"},{"key":"B62","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1172\/JCI34739","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K dependent feedback loop in human cancer","volume":"118","author":"Carracedo","year":"2008","journal-title":"J Clin Invest"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O\u00e2\u20ac\u2122Reilly","year":"2006","journal-title":"Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ccr.2010.10.021","article-title":"B55beta-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer","volume":"18","author":"Tan","year":"2010","journal-title":"Cancer Cell"},{"key":"B65","doi-asserted-by":"publisher","first-page":"E699","DOI":"10.1073\/pnas.1108237108","article-title":"PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis","volume":"108","author":"Ilic","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B66","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","article-title":"Myc on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell"},{"key":"B67","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1042\/BJ20130342","article-title":"Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors","volume":"452","author":"Sommer","year":"2013","journal-title":"Biochem J"},{"key":"B68","doi-asserted-by":"publisher","first-page":"5278","DOI":"10.1158\/1078-0432.CCR-12-0351","article-title":"Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma","volume":"18","author":"Rosich","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"115","DOI":"10.4161\/auto.22483","article-title":"Autophagy controls everolimus (RAD001) activity in mantle cell lymphoma","volume":"9","author":"Rosich","year":"2013","journal-title":"Autophagy"},{"key":"B70","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.bbcan.2010.07.003","article-title":"Autophagy is a therapeutic target in anticancer drug resistance","volume":"1806","author":"Chen","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"B71","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1101\/gad.186965.112","article-title":"Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy","volume":"26","author":"Logue","year":"2012","journal-title":"Genes Dev"},{"key":"B72","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ctrv.2011.02.002","article-title":"Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway","volume":"37","author":"Ribatti","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"B73","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.drup.2009.12.001","article-title":"Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy","volume":"13","author":"Abdollahi","year":"2010","journal-title":"Drug Resist Updat"}],"container-title":["Frontiers in Oncology"],"original-title":[],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T11:39:41Z","timestamp":1648813181000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2014.00064\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,14]]},"references-count":73,"URL":"https:\/\/doi.org\/10.3389\/fonc.2014.00064","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,14]]}}}